• HyperFluor 488 Goat Anti-Mouse IgG Guide

  2026-08-26

  HyperFluor 488 Goat Anti-Mouse IgG is a fluorescently labeled secondary antibody for detecting mouse IgG in immunofluorescence, flow cytometry, and western blotting. Its H+L binding profile supports broad mouse immunoglobulin recognition, while the reference endothelial study illustrates how fluorescence-based protein localization can complement DNA-damage and vascularization assays.

• Stable-Isotope UHPLC–MS/MS for Methylated Nucleosides

  2026-08-25

  Zhang, Zhang, and Wang developed a stable isotope-diluted UHPLC–ESI-MS/MS method for accurately measuring 12 purine ribonucleosides, including 10 methylated species such as 1-methyl Adenosine. Ammonium bicarbonate-assisted ionization, isomer-resolving chromatography, and methanol–SPE cleanup improved sensitivity for intracellular analysis and established a practical platform for RNA modification research and nucleoside biomarker discovery.

• HA-LNP PTEN mRNA for Transdermal Melanoma Therapy

  2026-08-25

  A 2026 Journal of Controlled Release study developed hyaluronate-conjugated lipid nanoparticles containing PTEN mRNA for topical, transdermal melanoma immunotherapy. The HA-DMG formulation combined nanoparticle stabilization with CD44-directed targeting, enabling skin and tumor penetration, PTEN restoration, immunogenic cell death, tumor growth suppression, and immune activation in preclinical models.

• Caspase-3/7 Inhibitor I: Applied Apoptosis Workflows

  2026-08-24

  Use Caspase-3/7 Inhibitor I as a reversible, cell-permeable perturbation to determine whether apoptosis depends on executioner caspases rather than simply measuring cell loss. This guide translates phase-specific Candida krusei findings into practical host-cell workflows, controls, washout experiments, and troubleshooting strategies.

• FDA Library Screening Reveals MERS-CoV Inhibitors

  2026-08-24

  de Wilde and colleagues screened an FDA-approved compound library and identified four molecules, including Lopinavir, that inhibited MERS-CoV replication in cell culture. The study established a practical repurposing framework for emerging coronavirus research while emphasizing that cellular activity requires validation in animal models and clinical settings.

• DiscoveryProbe Stem Cell Compound Library Plus

  2026-08-23

  Turn pathway breadth into an interpretable stem cell screening workflow with 280 curated bioactive compounds spanning self-renewal, differentiation, proliferation, and disease-relevant signaling. A high-content parasite stem-cell study shows how quantitative imaging and orthogonal validation can sharpen hit triage beyond morphology alone.

• Cy3 Goat Anti-Human IgG (H+L) Antibody Workflow

  2026-08-22

  Build brighter, more reproducible human IgG readouts across immunofluorescence, tissue staining, flow cytometry, and ELISA. This practical workflow shows how to use a Cy3 conjugated secondary antibody while controlling background, photobleaching, species mismatch, and matrix effects.

• Imatinib Hydrochloride: A Conformation-Aware Guide

  2026-08-22

  Imatinib hydrochloride is a versatile tool for dissecting v-Abl, c-Kit, and PDGFR signaling. This guide connects target inhibition with kinase-conformation biology to improve assay design in leukemia and gastrointestinal stromal tumor research.

• Purmorphamine: Smo Signaling for Cell Fate

  2026-08-21

  Purmorphamine is a Smoothened agonist that converts Hedgehog pathway biology into a practical tool for studying osteogenic signaling, neural degeneration, and sensory regulation. This article explains how to interpret its potency, design cross-system assays, and avoid misleading conclusions from dose transfer.

• Cucurbitacin I: A Causal STAT3 Assay Framework

  2026-08-20

  Cucurbitacin I, also known as JSI-124, can support a rigorous causal analysis of JAK2/STAT3 signaling in cancer models. This article presents a compartment-aware assay strategy inspired by human SAN-plexus assembloids, connecting molecular inhibition to invasion, apoptosis, and tumor growth inhibition in vivo.

• Dual-Action Inhibitors Alter p38α Dephosphorylation

  2026-08-20

  A bioRxiv preprint reports that selected kinase inhibitors can do more than block p38α MAP kinase activity: they also accelerate WIP1-mediated dephosphorylation by stabilizing an activation-loop conformation that exposes the phospho-threonine. The structural and biochemical findings suggest a way to design inhibitors that combine catalytic inhibition with phosphatase-favorable target remodeling.

• GTP Solution (100 mM) for Reliable RNA Workflows

  2026-08-19

  This scenario-driven guide shows how GTP quality, concentration control, nuclease management, and storage affect RNA synthesis workflows that feed cell proliferation and viability assays. It explains when GTP Solution (100 mM), SKU K1044, is a practical choice for reproducible bench-scale work and how to interpret downstream p21 mRNA-LNP results without over-attributing effects to the nucleotide reagent.

• Ibrutinib, CSK Inhibition, and Atrial Fibrillation

  2026-08-19

  The reference study identifies off-target inhibition of C-terminal Src kinase (CSK), rather than Bruton tyrosine kinase inhibition itself, as the mechanistic basis of ibrutinib-associated atrial fibrillation. By combining mouse electrophysiology, chemoproteomics, genetic validation, pharmacology, and pharmacovigilance, the authors establish a framework for connecting kinase selectivity with clinically important toxicity.

• Carvedilol Phosphate in Hepatic IRI Models

  2026-08-18

  Carvedilol Phosphate provides a defined beta-adrenergic signaling perturbation for hepatic and cardiovascular ischemia–reperfusion studies. This guide translates Arrb2–macrophage findings into practical formulation, assay, and troubleshooting workflows while clearly separating evidence from exploratory protocol choices.

• Tivozanib (AV-951) Assay Workflow Guide

  2026-08-18

  Build more informative anti-angiogenic experiments with Tivozanib (AV-951) by separating growth inhibition from true cell killing. This practical workflow combines VEGFR-focused pathway assays, viability kinetics, and combination testing to improve interpretation in renal cell carcinoma and broader oncology models.

541 records 6/37 page Previous Next First page 上5页 678910 下5页 Last page